Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FTC Homeopathic Advertising Review Spurs Broader Disclaimer Suggestion, Opens New Stage For RCT Debate

This article was originally published in The Tan Sheet

Executive Summary

FTC attorneys say homeopathic claims should meet the same standard of proof the commission contends is required for dietary supplement advertising – randomized, controlled clinical trials. An industry groups says 92%-99% of participants in its study understood FDA does not review homeopathic drug label claims.


Related Content

OTC Homeopathic Labels Must Include Scientific Disclaimers – FTC
Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers